Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MLYCD | O95822 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 3/20 | 0.35 |
| ▸ | THRA | P10827 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344395 | 0.86 | ZDHHC20 (0.61) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL12731248 | 0.85 | ZDHHC20 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL24119207 | 0.84 | ZDHHC20 (0.65) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL29386805 | 0.84 | ZDHHC20 (0.59) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL8766172 | 0.83 | ZDHHC20 (0.48) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL635849 | 0.83 | ZDHHC20 (0.48) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL24932662 | 0.83 | ZDHHC20 (0.48) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL27495249 | 0.83 | ZDHHC20 (0.62) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL15338435 | 0.82 | SIGMAR1 (0.42) | ZDHHC20ZDHHC2ALDH1A1SIGMAR1MLYCD | |
| Hydrochloric Acid SCHEMBL406600 | 0.82 | ZDHHC20 (0.47) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20230132202-A1 | Polymeric Binder and High Molecular Weight Polymer Antifouling Compositions | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-04-27 | — | — | US | disclosed |
| US-20230132202-A1 | Polymeric Binder and High Molecular Weight Polymer Antifouling Compositions | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-04-27 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-6932964-B1 | Copolymer of a tert-butyl acrylate and/or an N-tert-butylacrylamide, at least acrylic mono- and/or dicarboxylic acid, and at least one ethoxylated acrylic compound; high propellant gas compatibility and no \"flaking\" effect; hair sprays | BASF AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20030147929-A1 | Contains a water-dispersible copolymer containing units of a tert-butyl acrylate or tert-butyl acrylamide of given formula, an N-vinylamide or N-vinyllactam, an unsaturated cationic amine, and optional acrylic type monomer; hair spray | BASF SE (DE) | 2003-08-07 | — | — | US | disclosed |
| US-6329472-B1 | COSMETIC PREPARATIONS, SUCH AS HAIR-SETTING FORMULATIONS | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | ZDHHC20 1684/4885ZDHHC2 2178/4885TSHR 4515/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ZDHHC20 1528/4885ZDHHC2 816/4885TSHR 4752/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | ZDHHC20 1684/4885ZDHHC2 2178/4885TSHR 4515/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | ZDHHC20 1457/4885ZDHHC2 1872/4885TSHR 4635/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ZDHHC20 1003/4885ZDHHC2 1199/4885TSHR 3523/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | ZDHHC20 1528/4885ZDHHC2 816/4885TSHR 4752/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ZDHHC20 690/4885ZDHHC2 886/4885TSHR 4633/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ZDHHC20 958/4885ZDHHC2 905/4885TSHR 2837/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ZDHHC20 1528/4885ZDHHC2 816/4885TSHR 4752/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ZDHHC20 690/4885ZDHHC2 886/4885TSHR 4633/4885 |
| US-20030147929-A1 | Contains a water-dispersible copolymer containing units of a tert-butyl acrylate or tert-butyl acrylamide of given formula, an N-vinylamide or N-vinyllactam, an unsaturated cationic amine, and optional acrylic type monomer; hair spray | HVCN1, NR2C2, ARCN1 | ZDHHC20 1361/4885ZDHHC2 563/4885TSHR 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.